We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




AI Algorithm Automates Cystic Fibrosis CT Scan Analysis

By HospiMedica International staff writers
Posted on 06 Apr 2021
A new artificial intelligence (AI) algorithm can analyze CT scans of cystic fibrosis (CF) patients in several seconds, without human interference.

The Thirona (Nijmegen, The Netherlands) Pragma-AI is designed to automatically identify lung abnormalities related to CF, such as collapsed lung tissue and abnormal airways. More...
Sensitive, objective information on the pattern and extent of CF lung disease is immediately available, helping clinicians monitor disease progression and supporting clinical treatment planning. Pragma-AI is part of the company’s LungQ quantification software package, which precisely detects emphysematous regions in the lungs, air-trapping, airway morphology, and fissure completeness.

“Artificial intelligence algorithms make medical image analysis easier, more accurate and more effective; but it is hard work. Developing an algorithm that works as well as, and sometimes even better than a clinician, takes time,” said Eva van Rikxoort, Managing Director of Thirona. “The algorithm will be able to quickly and accurately detect bronchiectasis and mucous quantifications in very young patients with CF, making personalized treatment easier.”

“These developments pave the way for using the PRAGMA method in both clinical trials and clinical care. It allows for large scale investigation of CF lung disease in both research studies and clinical trials. This is a crucial component in the evaluation of new expensive treatment options for patients suffering from CF,” said Professor Harm Tiddens, MD, of Erasmus Medical Center (Rotterdam, The Netherlands). “CF patient registries, collecting information on the health status of CF patients, have already shown interest in the PRAGMA-AI method.”

CF is an autosomal recessive genetic disorder that affects mainly the lungs, but also the pancreas, liver, and intestine. It is characterized by abnormal transport of chloride and sodium across an epithelium, leading to thick, viscous secretions. The name refers to the characteristic scarring (fibrosis) and cyst formation within the pancreas, first recognized in the 1930’s. Difficulty breathing is the most serious symptom, resulting from frequent lung infections that are usually treated with antibiotics and other medications.

Related Links:
Thirona


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.